Amplify Treatments, Testing and Advancements ETF
GERM
GERM was delisted on the 5th of September, 2024.
17 hedge funds and large institutions have $3.43M invested in Amplify Treatments, Testing and Advancements ETF in 2023 Q2 according to their latest regulatory filings, with 2 funds opening new positions, 2 increasing their positions, 3 reducing their positions, and 4 closing their positions.
20% more capital invested
Capital invested by funds: $2.85M → $3.43M (+$574K)
11% less funds holding
Funds holding: 19 → 17 (-2)
33% less repeat investments, than reductions
Existing positions increased: 2 | Existing positions reduced: 3
50% less first-time investments, than exits
New positions opened: 2 | Existing positions closed: 4
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$678K |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$588K |
| 3 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
+$250K |
| 4 |
UBS Group
Zurich,
Switzerland
|
+$51.4K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
LPL Financial
San Diego,
California
|
-$345K |
| 2 |
GBWM
Granite Bay Wealth Management
Portsmouth,
New Hampshire
|
-$260K |
| 3 |
IAIM
International Assets Investment Management
Orlando,
Florida
|
-$240K |
| 4 |
Commonwealth Equity Services
Waltham,
Massachusetts
|
-$54.8K |
| 5 |
BAM
Belpointe Asset Management
Reno,
Nevada
|
-$36.5K |
GERM Hedge Fund Activity: Q2 2023 in Review
17 of the 6,383 institutional investors tracked by Wall St. Rank reported a position in Amplify Treatments, Testing and Advancements ETF (GERM) for Q2 2023, worth a combined $3.43M — up 20% from $2.85M a quarter earlier.
Sellers outnumbered buyers: 4 funds closed out of GERM and 2 opened new positions — a net loss of 2 holders — while 3 trimmed existing stakes and 2 added.
The largest buyer was Goldman Sachs, adding an estimated $678K. The largest seller was LPL Financial, cutting an estimated $345K.
- 17 institutional investors held Amplify Treatments, Testing and Advancements ETF (GERM) as of Q2 2023, down from 19 in Q1 2023.
- Funds reported $3.43M of Amplify Treatments, Testing and Advancements ETF stock for Q2 2023, up 20% quarter-over-quarter.
- 2 funds opened new Amplify Treatments, Testing and Advancements ETF positions in Q2 2023 and 4 closed out, a net change of -2 holders.
- The largest Amplify Treatments, Testing and Advancements ETF buyer in Q2 2023 was Goldman Sachs, an estimated $678K added.
- The largest Amplify Treatments, Testing and Advancements ETF seller in Q2 2023 was LPL Financial, an estimated $345K sold.
Based on aggregated 13F filings for Q2 2023.